ArticleBMC cancer2021

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.

Wolfram Samlowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.